Baxter International Inc.

BAX ·Healthcare, Medical Devices, United States

Baxter International Inc. (BAX)

Overview

Baxter International is a global medical technology company that develops, manufactures, and markets products used to treat patients in hospitals, clinics, and at home — from IV fluids and infusion pumps to surgical hemostats and connected patient-monitoring systems. It is headquartered in Deerfield, Illinois, and sits in the Health Care sector under the medical devices/supplies industry. Following its August 2024 announcement (completed in early 2025) to divest its Kidney Care/Vantive business to the Carlyle Group for $3.8 billion, Baxter is now a more focused medtech company, reporting continuing-operations revenue of roughly $11.2 billion for full-year 2025 and employing approximately 37,500 people serving customers in over 100 countries.

What They Do & How They Make Money

Baxter makes money manufacturing and selling medical products that hospitals and other care providers consume repeatedly — a classic "razor and razorblade" model in parts of its business (infusion pumps and the disposable sets/solutions that run through them) combined with capital-equipment sales (surgical devices, hospital beds, monitors). Its core essential products — sterile IV solutions, infusion systems, and parenteral nutrition — are used in nearly every hospital and are difficult for providers to substitute, giving Baxter durable, recurring revenue. It also earns revenue from specialty injectable pharmaceuticals, inhaled anesthesia, and compounded drugs administered in acute-care settings, as well as from surgical adhesives/sealants and hemostats used in operating rooms. On the technology side, it sells connected-care platforms (smart hospital beds, patient monitoring and diagnostic systems) and operating-room integration equipment, often bundled with service and software contracts. Revenue is generated globally, with the U.S. as the largest single market, and much of its book is tied to hospital capital and consumable purchasing cycles as well as group purchasing organization (GPO) contracts.

Business Segments

Following a 2026 reorganization that folded the former Pharmaceuticals segment into its infusion business and consolidated reporting after the Kidney Care divestiture, Baxter now operates through two primary reportable segments:

Medical Products & Therapies (MPT) — the larger segment ($7.8B in 2025 net sales, $1.68B segment operating income), comprising: (1) Infusion Therapies & Platforms — sterile IV solutions, infusion pumps and administration sets, parenteral nutrition, specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding; and (2) Advanced Surgery — surgical hemostats, sealants, and adhesion-prevention products used in the OR.
Healthcare Systems & Technologies (HST) — ($3.1B in 2025 net sales, $565M segment operating income), comprising: (1) Front Line Care — respiratory health devices and surgical/OR integration and positioning equipment; and (2) Care & Connectivity Solutions — smart hospital beds, patient-monitoring systems, and diagnostic technologies.

Prior to the sale to Carlyle, Baxter also operated a Kidney Care segment (dialysis products and services, now branded Vantive under its new owner), which is excluded from continuing operations in current filings.

Competitors

Baxter's competitive set varies significantly by product line:

IV solutions/infusion & medication delivery: Becton Dickinson (BDX), ICU Medical, Fresenius Kabi, B. Braun.
Advanced surgery (hemostats/sealants): Johnson & Johnson (Ethicon), Stryker, CSL Behring (Baxalta legacy overlap).
Connected care / hospital beds & monitoring: Stryker, Hillrom's former rivals (now part of Baxter), GE HealthCare, Philips.
Anesthesia/pharmaceuticals: Fresenius Kabi, Pfizer Hospira, generic injectable manufacturers.
Dialysis (for context, now a divested but related market): Fresenius Medical Care, DaVita.

Competitive Position

Baxter's core competitive advantage is the essentiality and installed base of its products: IV solutions, infusion pumps, and basic hospital consumables are used in virtually every acute-care setting, and switching costs are high once a hospital system has standardized on Baxter's infusion platforms, pump software, and service contracts. This gives the company durable, high-visibility recurring revenue and leading U.S. market share in core fluids and infusion. The 2021 acquisition of Hillrom (smart beds, patient monitoring, connectivity) was intended to build a broader "connected care" ecosystem spanning bedside devices and infusion, though integration has progressed more slowly than originally planned. The divestiture of Kidney Care/Vantive materially simplified the portfolio, freed up capital to pay down debt (targeting net leverage near 3.0x by the end of 2026), and let management — under new CEO Andrew Hider, who took over in August 2025 — focus on operational execution and margin improvement in the remaining higher-growth, higher-margin businesses.

Key risks include pricing pressure from powerful hospital group purchasing organizations that can squeeze margins on commodity-like products such as IV solutions; manufacturing concentration risk, illustrated by damage to its North Cove, North Carolina IV-fluid plant from Hurricane Helene in 2024, which caused supply disruptions and highlighted vulnerability to climate/weather events; ongoing FDA regulatory scrutiny of device manufacturing and connected/software-enabled products; and execution risk in fully realizing synergies from the Hillrom deal while simultaneously carrying a leveraged balance sheet post-divestiture. Slower hospital capital spending, inflation in input costs, and intensifying competition from larger, more diversified med-tech peers (J&J, Stryker, Becton Dickinson) round out the company's principal challenges.